


NR4A2-HuR axis is a novel target for treating pancreatic cancer

Supplementary Table 1. Sources of oligonucleotides

A. Sources of siRNAs (life technologies)	
siRNA oligos	Catalog
siNR4A2	s9787
siELAVL1/HuR	s4609
siSp1	s13319
siSp3	s13325
siSp4	s13327
siCTRL	AM4635


B. ChIP primers	
IDH1	HuR
ChIP F1: GAGCAAGGCCCTGTCTTAAA	ChIP F1: GCAAGACCTCATCGCTACAA
ChIP R1: GTTACCTGCCGGGATGATATG	ChIP R1: CTCCCAAAGAGCTGGGATTAC
ChIP F2: TGGAAAATCGAGGGGTGGAA	ChIP F2: CATCCAGGTGAGGCGGTG
ChIP R2: TATCACCCGTCCTATGGCC	ChIP R2: GTAGCTGGCCCCACTCTC
ChIP Primer 1:	ChIP Primer1:
Forward: GAGCAAGGCCCTGTCTTAAA	Forward: GCAAGACCTCATCGCTACAA
Reverse: GTTACCTGCCGGGATGATATG	Reverse: CTCCCAAAGAGCTGGGATTAC




C. RT-PCR primers (life sciences)	
NR4A2	Forward: CGACATTCTGCCTTCTCC Reverse: GGTAAGTGTCCAGGAAAAG
IDH1	Forward: CTATGATGGTGACGTGCAGTG Reverse: CCTCTGCTTCTACTGTCTTGCC
HuR	Forward: AACGCCTCCTCCGGCTGGTG Reverse: GCG GTA GCC GTTCAGGCTGG

NR4A2-HuR axis is a novel target for treating pancreatic cancer

A



B



Supplementary Figure 1. NR4A2 knockout induces alterations in multiple genes and pathways in MiaPaCa2 cells. A. Partial least squares discriminant analysis (PLS-DA) plot analyzed by LC-MS/MS performed on NR4A2^(+/+) and NR4A2^(-/-) cells. B. Metabolite set enrichment analysis in NR4A2 knockout MiaPaCa2 cells.